News

To err is human; to forgive, divine. Or is it? Research on the brain’s structural anatomy and activity provide insight into the science of forgiveness.

The Director of Cleveland Clinic Lou Ruvo Center for Brain Health spoke about the rapidly changing landscape of treatments for Alzheimer disease.

Despite concerns amid reports of deaths and serious adverse events, the FDA has confirmed the safety profile of the therapy has remained consistent.

The Carl F. Asseff Professor of Ophthalmology and the Director of the Visual Sciences Research Center at Case Western Reserve University further discussed the trial of efavirenz in AD.

Silberstein spoke about the new mechanism-based treatments that are revolutionary in changing the treatment landscape of migraine.

The Johns Hopkins Associate Professor spoke about the current therapeutic landscape of restless leg syndrome, an often misdiagnosed disorder.

Neurology News Network for the week of September 22, 2018.

While PES has been debated as a successful therapy for post-stroke dysphagia, recent data has suggested it may be efficacious.

For the associate professor of neurology, learning, listening, and collaborating are the keys to improving the field of care.

The Jim Turner Chair in Cognitive Disorders at the Vanderbilt University School of Medicine explained more about the molecule and the subsequent trial of it.

Patients with stroke should receive screening for sleep apnea in the short-term event period, receiving treatment with continuous positive airway pressure.

The RLS expert explained his best practices for treating patients who develop augmentation after treatment.

A 64-year-old man, who has been a smoker for 40 years, presents at urgent care with dizziness, persistent hiccups, and dizziness. What's your diagnosis?

The associate chief of clinical pediatric neurology, director of the pediatric neurophysiology lab, and director at the Adolescent Epilepsy Center at UCLA spoke about therapeutic options for pediatric epilepsy.

With a heavy focus on the need for new treatments in Alzheimer, there remains a need to ensure patients are cared for first and foremost.

M. Scott Perry, MD, spoke about the industry's excitement surrounding the current treatment landscape for pediatric epilepsy.

Novel biomarkers are being explored to help expedite the development of new treatments for Alzheimer disease.

Could the introduction of gene therapies into the Alzheimer space be the beginning of a new era of treatment?

The associate professor of neurology at Mayo Clinic spoke about targeting mitochondria to treat neurologic disorders.

Ensuring patients quality of life is still being attended to is of utmost importance to the director of the Comprehensive Multiple Sclerosis Center at Stony Brook University.

The Medical Director of Neurology and Justin Neurosciences Center at Cook Children's Medical Center spoke about the importance of staying up-to-date and informed about this rapidly changing space.

Practice guidelines for the management of low-level, minimally conscious states resulting from brain injury include recommendations for assessment, treatment protocol, and supportive approaches.

The ADDF's founding executive director and chief scientific officer spoke about the gains in clinical trials in the last 5 years.

Allogeneic mesenchymal stem cells manufactured by Longeveron are advancing through phase I and II clinical trials.

The chairman of the Department of Genetic Medicine at Weill Cornell Medicine shared his experience with the therapy and its potential in the space.

Memory decline was worse for patients with MCI receiving supportive therapy over behavioral activation.

The assistant professor of neurology and neurosurgery spoke about the need to identify LVO in the field, quickly, to improve care.

The director of the Comprehensive Multiple Sclerosis Center at Stony Brook Neuroscience Institute discussed these needs.